Please assess the completion status of the following clinical trial:

Trial Title: Fluticasone Nasal Spray Patient Preference Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* allergic rhinitis~* literate~Exclusion Criteria:~* clinical significant uncontrolled disease~* Use of intranasal corticosteroids (\<4 weeks of FP \[branded or generic\],\<4 week exposure to FF, \<4 weeks use of other INS)~* Use of intranasal medications \<1 week~* Use of meds that significantly inhibit CYP4503A4~* Use of perfume or oral rinse on study day~* Allergy/intolerance to INS, antihistamines, or excipients~* Positive pregnancy test or female who is breastfeeding~* Affiliation with investigational site

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- fluticasone propionate (FP) (Type: ACTIVE_COMPARATOR): 200 micrograms (mcg); an aqueous suspension of microfine FP
- fluticasone furoate (FF) (Type: ACTIVE_COMPARATOR): 110 mcg; an aqueous suspension containing 0.05% w/w of micronized FF

Based on this trial design, predict the completion outcome and termination type (if applicable).